Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Hue Tu Quach, Zhaohua Hou, Rebecca Y. Bellis, Jasmeen K. Saini, Alfredo Amador-Molina, Prasad S. Adusumilli & Yuquan Xiong. (2022) Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1. Expert Opinion on Investigational Drugs 31:11, pages 1187-1202.
Read now
Read now
Prabha Singh, Pramita Waghambare, Tabassum Asif Khan & Abdelwahab Omri. (2022) Colorectal cancer management: strategies in drug delivery. Expert Opinion on Drug Delivery 19:6, pages 653-670.
Read now
Read now
Yan Tie, Hui Yang, Rui Zhao, Heng Zheng, Daoke Yang, Jingyi Zhao & Ming Liu. (2019) Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis. Drug Design, Development and Therapy 13, pages 523-538.
Read now
Read now
Erika J. Crosby, Junping Wei, Xiao Yi Yang, Gangjun Lei, Tao Wang, Cong-Xiao Liu, Pankaj Agarwal, Alan J. Korman, Michael A. Morse, Kenneth Gouin, Simon R. V. Knott, H. Kim Lyerly & Zachary C. Hartman. (2018) Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. OncoImmunology 7:5.
Read now
Read now
Jiali Yang, Juan Chen, Jun Wei, Xiaoming Liu & William C. Cho. (2016) Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. Expert Opinion on Biological Therapy 16:10, pages 1209-1223.
Read now
Read now
Rosa M Michel Ortega & Harry A Drabkin. (2015) Nivolumab in renal cell carcinoma. Expert Opinion on Biological Therapy 15:7, pages 1049-1060.
Read now
Read now
Articles from other publishers (54)
Paulina Śledzińska, Marek Bebyn, Jacek Furtak, Agnieszka Koper & Krzysztof Koper. (2023) Current and promising treatment strategies in glioma. Reviews in the Neurosciences 34:5, pages 483-516.
Crossref
Crossref
Xuewei Sun, Qian Cui, Juan Ni, Xiaoguang Liu, Jin Zhu, Tingting Zhou, HuaYing Huang, Ke OuYang, Yulong Wu & Zhan Yang. (2023) Retracted and Republished from: “Gut Microbiota Mediates the Therapeutic Effect of Monoclonal Anti-TLR4 Antibody on Acetaminophen-Induced Acute Liver Injury in Mice”. Microbiology Spectrum 11:2.
Crossref
Crossref
Susana Cortijo-Cascajares, Ana Cristina Cercós-Lletí, Sara Ortiz-Pérez, José Manuel Caro-Teller & José Miguel Ferrari-Piquero. (2021) Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness. Journal of Oncology Pharmacy Practice 29:2, pages 290-298.
Crossref
Crossref
Joel Yong, Albert S. Mellick, John Whitelock, Joseph Wang & Kang Liang. (2023) A Biomolecular Toolbox for Precision Nanomotors. Advanced Materials, pages 2205746.
Crossref
Crossref
Yousra A. Hagyousif, Basma M. Sharaf, Ruba A. Zenati, Waseem El-Huneidi, Yasser Bustanji, Eman Abu-Gharbieh, Mohammad A. Y. Alqudah, Alexander D. Giddey, Ahmad Y. Abuhelwa, Karem H. Alzoubi, Nelson C. Soares & Mohammad H. Semreen. (2023) Skin Cancer Metabolic Profile Assessed by Different Analytical Platforms. International Journal of Molecular Sciences 24:2, pages 1604.
Crossref
Crossref
Sitanshu Mondal, Vishakha S., Kumari Das Kajal, Simranpreet K. Wahan, Balak Das Kurmi & Preeti Patel. (2023) Current Trends in the Development of EGFR Inhibitors as Promising Anticancer
Agents: Sar and Synthetic Studies from (2010-2020). Current Organic Chemistry 27:1, pages 2-27.
Crossref
Crossref
Satoshi Nakagawa, Mariko Shindo, Yutaka Ueda, Tadashi Kimura & Koji Matsuo. 2020. Handbook of Gynecology. Handbook of Gynecology
1
20
.
Satoshi Nakagawa, Mariko Shindo, Yutaka Ueda, Tadashi Kimura & Koji Matsuo. 2023. Handbook of Gynecology. Handbook of Gynecology
931
950
.
Antonio G. Solimando & Domenico Ribatti. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
21
.
Toshihiko Tashima. (2022) Delivery of Drugs into Cancer Cells Using Antibody–Drug Conjugates Based on Receptor-Mediated Endocytosis and the Enhanced Permeability and Retention Effect. Antibodies 11:4, pages 78.
Crossref
Crossref
Mohammadsaleh Jahangir, Omid Yazdani, Mohammad Saeed Kahrizi, Sara Soltanzadeh, Hamidreza Javididashtbayaz, Azam Mivefroshan, Saba Ilkhani & Romina Esbati. (2022) Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. Cancer Cell International 22:1.
Crossref
Crossref
Tae-Jun Jeong, Hyun-Tae Lee, Nahyeon Gu, Yu-Jeong Jang, Seung-Beom Choi, Ui-Beom Park, Sang-Hyung Lee & Yong-Seok Heo. (2022) The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy. Biomedicines 10:12, pages 3154.
Crossref
Crossref
Bahman Abedi Kiasari, Arash Abbasi, Nadia Ghasemi Darestani, Nasim Adabi, Arsalan Moradian, Yalda Yazdani, Golsa Sadat Hosseini, Nasrin Gholami & Sheida Janati. (2022) Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy. International Immunopharmacology 113, pages 109365.
Crossref
Crossref
Yann‐Alexandre Vano, Letuan Phan, Gwenaelle Gravis, Iphigénie Korakis, Friederike Schlürmann, Denis Maillet, Mostefa Bennamoun, Nadine Houede, Delphine Topart, Delphine Borchiellini, Philippe Barthelemy, Raffaele Ratta, Thomas Ryckewaert, Ali Hasbini, Sophie Hans, Sheik Emambux, Sandra Cournier, Elena Braychenko, Réza‐Thierry Elaidi & Stéphane Oudard. (2022)
Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The
CABIR
study
. International Journal of Cancer 151:8, pages 1335-1344.
Crossref
Crossref
Tiago Biachi de Castria, Danny N Khalil, James J Harding, Eileen M O'Reilly & Ghassan K Abou-Alfa. (2022) Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma. Future Oncology 18:33, pages 3769-3782.
Crossref
Crossref
Toshihiko Tashima. (2022) Brain Cancer Chemotherapy through a Delivery System across the Blood-Brain Barrier into the Brain Based on Receptor-Mediated Transcytosis Using Monoclonal Antibody Conjugates. Biomedicines 10:7, pages 1597.
Crossref
Crossref
Adel Naimi, Rebar N. Mohammed, Ahmed Raji, Supat Chupradit, Alexei Valerievich Yumashev, Wanich Suksatan, Mohammed Nader Shalaby, Lakshmi Thangavelu, Siavash Kamrava, Navid Shomali, Armin D. Sohrabi, Ali Adili, Ali Noroozi-Aghideh & Ehsan Razeghian. (2022) Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Communication and Signaling 20:1.
Crossref
Crossref
Guofeng Ma, Chun Li, Zhilei Zhang, Ye Liang, Zhijuan Liang, Yuanbin Chen, Liping Wang, Dan Li, Manqin Zeng, Wenhong Shan & Haitao Niu. (2021) Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies. Frontiers in Oncology 11.
Crossref
Crossref
Burcin Özdirik, Fabian Jost-Brinkmann, Lynn Jeanette SavicRaphael Mohr, Frank Tacke, Christoph J. Ploner, Christoph RoderburgTobias Müller. (2021) Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma. Medicine 100:24, pages e26377.
Crossref
Crossref
Yuan Hong, Yingcai Feng, Hanzi Sun, Bo Zhang, Hongfu Wu, Qing Zhu, Yucheng Li, Tong Zhang, Yilu Zhang, Xinxin Cui, Zhuo Li, Xiaomin Song, Kang Li, Mike Liu & Ye Liu. (2021) Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage. FEBS Open Bio 11:3, pages 782-792.
Crossref
Crossref
Zachary DavisMartin FelicesTodd LenvikSujan BadalJoshua T. WalkerPeter HinderlieJames L. Riley, Daniel A. Vallera, Bruce R. Blazar & Jeffrey S. Miller. (2021) Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. Blood Advances 5:4, pages 1069-1080.
Crossref
Crossref
Liwei Liu, Mingya Yang, Qia Xu, Min Zhou, Yan Cheng, Heming Xu, Yide Qin & Bo Liu. (2021) Killing efficiency affected by mutually modulated PD-1 and PD-L1 expression via NKT-hepatoma cell interactions. Immunotherapy 13:2, pages 113-123.
Crossref
Crossref
Domenico Ribatti. 2021. Tumor Microenvironment Regulation of Tumor Expansion. Tumor Microenvironment Regulation of Tumor Expansion
139
154
.
Jifeng Yu, Yongping Song & Wenzhi Tian. (2020) How to select IgG subclasses in developing anti-tumor therapeutic antibodies. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Xiaoxiao Ye, Min Tu, Mingxin Piao, Liang Yang, Zeng Zhou, Zhaopeng Li, Meiyu Lin, Zhenming Yang & Zecheng Zuo. (2020) Using phage-assisted continuous evolution (PACE) to evolve human PD1. Experimental Cell Research 396:1, pages 112244.
Crossref
Crossref
Koichi Ando, Yasunari Kishino, Tetsuya Homma, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi & Hironori Sagara. (2020) Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Cancers 12:7, pages 1905.
Crossref
Crossref
Ilenia Aversa, Donatella Malanga, Giuseppe Fiume & Camillo Palmieri. (2020) Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy. International Journal of Molecular Sciences 21:7, pages 2378.
Crossref
Crossref
Paola Ciciola, Priscilla Cascetta, Cataldo Bianco, Luigi Formisano & Roberto Bianco. (2020) Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. Journal of Clinical Medicine 9:3, pages 675.
Crossref
Crossref
Li Wang, Deze Zhao, Kang Qin, Faisal UL Rehman & Xiaochun Zhang. (2019) Effect and biomarker of Nivolumab for non–small-cell lung cancer. Biomedicine & Pharmacotherapy 117, pages 109199.
Crossref
Crossref
Hyun Lee, Sang Lee & Yong-Seok Heo. (2019) Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. Molecules 24:6, pages 1190.
Crossref
Crossref
Jianjun Jin, Jiming Si, Yuanhua Liu, Huanqin Wang, Ran Ni & Jing Wang. (2018) Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy. Respiratory Research 19:1.
Crossref
Crossref
Yu Yu & Jiuwei Cui. (2018) Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review). Oncology Letters.
Crossref
Crossref
Xin Sun, Xiao Yan, Wei Zhuo, Jinke Gu, Ke Zuo, Wei Liu, Li Liang, Ya Gan, Gang He, Hua Wan, Xiaojun Gou, Hubing Shi & Jianping Hu. (2018) PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations. International Journal of Molecular Sciences 19:7, pages 1984.
Crossref
Crossref
Gabriel Gazzé. (2018) Combination therapy for metastatic melanoma: a pharmacist's role, drug interactions & complementary alternative therapies. Melanoma Management 5:2, pages MMT07.
Crossref
Crossref
Xiao Xiang, Peng-Cheng Yu, Di Long, Xiao-Li Liao, Sen Zhang, Xue-Mei You, Jian-Hong Zhong & Le-Qun Li. (2017) Prognostic value of PD -L1 expression in patients with primary solid tumors. Oncotarget 9:4, pages 5058-5072.
Crossref
Crossref
Veerendra Koppolu & Veneela Krishna Rekha Vasigala. (2018) Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. Journal of Cancer Research and Therapeutics 14:6, pages 1167-1175.
Crossref
Crossref
Bing Xia & Roy S. Herbst. 2018. Lung Cancer: A Practical Approach to Evidence-Based Clinical Evaluation and Management. Lung Cancer: A Practical Approach to Evidence-Based Clinical Evaluation and Management
99
115
.
J. Coy, A. Caldwell, L. Chow, A. Guth & S. Dow. (2017) PD-1 expression by canine T cells and functional effects of PD-1 blockade. Veterinary and Comparative Oncology 15:4, pages 1487-1502.
Crossref
Crossref
Fei Zhang, Xiaoqiang Qi, Xiaoxiao Wang, Diyang Wei, Jiawei Wu, Lingling Feng, Haiyan Cai, Yugang Wang, Naiyan Zeng, Ting Xu, Aiwu Zhou & Ying Zheng. (2017) Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget 8:52, pages 90215-90224.
Crossref
Crossref
Moritz Jesinghaus, Katja Steiger, Julia Slotta-Huspenina, Enken Drecoll, Nicole Pfarr, Petra Meyer, Björn Konukiewitz, Marcus Bettstetter, Kathrin Wieczorek, Katja Ott, Markus Feith, Rupert Langer, Wilko Weichert, Katja Specht & Melanie Boxberg. (2017) Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping. Oncotarget 8:29, pages 46756-46768.
Crossref
Crossref
Hyun Tae Lee, Ju Yeon Lee, Heejin Lim, Sang Hyung Lee, Yu Jeong Moon, Hyo Jeong Pyo, Seong Eon Ryu, Woori Shin & Yong-Seok Heo. (2017) Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Scientific Reports 7:1.
Crossref
Crossref
Yan Tie, Xuelei Ma, Chenjing Zhu, Ye Mao, Kai Shen, Xiawei Wei, Yan Chen & Heng Zheng. (2017) Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials. International Journal of Cancer 140:4, pages 948-958.
Crossref
Crossref
Mariko Shindo, Yutaka Ueda, Tadashi Kimura & Koji Matsuo. 2017. Handbook of Gynecology. Handbook of Gynecology
1
18
.
Ju Yeon Lee, Hyun Tae Lee, Woori Shin, Jongseok Chae, Jaemo Choi, Sung Hyun Kim, Heejin Lim, Tae Won Heo, Kyeong Young Park, Yeon Ji Lee, Seong Eon Ryu, Ji Young Son, Jee Un Lee & Yong-Seok Heo. (2016) Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nature Communications 7:1.
Crossref
Crossref
Paul E. Hughes, Sean Caenepeel & Lawren C. Wu. (2016) Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends in Immunology 37:7, pages 462-476.
Crossref
Crossref
Mei-Miao Zhan, Xue-Qin Hu, Xiu-Xiu Liu, Ban-Feng Ruan, Jun Xu & Chenzhong Liao. (2016) From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discovery Today 21:6, pages 1027-1036.
Crossref
Crossref
Ziying Lin, Yutong Xu, Yaxiong Zhang, Qihua He, Jianrong Zhang, Jianxing He & Wenhua Liang. (2016) The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures. Oncotarget 7:12, pages 15033-15046.
Crossref
Crossref
Bing Xia & Roy S Herbst. (2016) Immune checkpoint therapy for non-small-cell lung cancer: an update. Immunotherapy 8:3, pages 279-298.
Crossref
Crossref
Mario Orozco-Morales, Giovanny Soca-Chafre, Pedro Barrios-Bernal, Norma Hernández-Pedro & Oscar Arrieta. (2016) Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer. Mediators of Inflammation 2016, pages 1-11.
Crossref
Crossref
Mariko Shindo, Yutaka Ueda, Tadashi Kimura & Koji Matsuo. 2016. Handbook of Gynecology. Handbook of Gynecology
1
18
.
Fouad Aoun, Hampig R Kourie, Spyridon Sideris, Thierry Roumeguère, Roland van Velthoven & Thierry Gil. (2015) Checkpoint inhibitors in bladder and renal cancers: results and perspectives. Immunotherapy 7:12, pages 1259-1271.
Crossref
Crossref
Yoshie Kametani, Asuka Miyamoto, Banri Tsuda & Yutaka Tokuda. (2015) B Cell Epitope-Based Vaccination Therapy. Antibodies 4:3, pages 225-239.
Crossref
Crossref
Tom Powles. (2015) Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg?. European Urology 68:2, pages 280-282.
Crossref
Crossref
Giorgio Parmiani, Cristina Maccalli & Michele Maio. (2015) Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy. Vaccines 3:2, pages 420-428.
Crossref
Crossref